Batoclimab Biosimilar - Research Grade

Human

FcRn

>1mg/ml

Human IgG1-Lambda2

Nipocalimab Biosimilar - Research Grade (ICH5050), Rozanolixizumab Biosimilar - Research Grade (ICH5051), Efgartigimod Biosimilar - Research Grade (ICH5223), Orilanolimab Biosimilar - Research Grade (ICH5744)

https://www.imgt.org/mAb-DB/

ICH3002

P55899

2217

RRID:AB_2921591

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-FcRn antibody batoclimab, produced for research use only and built around the human neonatal Fc receptor (FcRn) target. It is not the clinical drug and is not intended for human or veterinary use. Batoclimab is a fully human IgG1 antibody that binds the neonatal Fc receptor and blocks the site where FcRn engages the Fc region of IgG, thereby shortening the half-life of circulating IgG, including pathogenic autoantibodies. As a research reagent, this analog is useful as a positive control and benchmarking tool in FcRn-binding and IgG-recycling assays, for comparability and bridging studies against in-house anti-FcRn candidates, for epitope-competition and blocking experiments, and for cell-based and biochemical characterization of FcRn interactions. It is supplied at research grade with low endotoxin (typically under 1 EU/mg, with an ultra-low option under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support assay development, in-vitro mechanistic work, and preclinical characterization. No clonal identity is implied. The neonatal Fc receptor (FcRn), encoded by FCGRT (UniProt P55899) and paired with beta-2-microglobulin, is an MHC class I-like receptor that governs the long serum half-life of IgG and albumin. After fluid-phase endocytosis, IgG binds FcRn in a strictly pH-dependent manner: engagement of the IgG Fc CH2-CH3 interface is strong in the acidic endosome (around pH 6) and negligible at near-neutral blood pH. Bound IgG is diverted away from lysosomal degradation and recycled back to the cell surface, where the neutral extracellular pH triggers release. This salvage pathway, together with a parallel albumin-binding site, extends IgG persistence and mediates transcytosis across epithelia, including maternal-to-fetal transfer. Blocking FcRn removes this protection, accelerating catabolism of total IgG and, therapeutically, of pathogenic autoantibodies.

IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, IgG receptor FcRn large subunit p51, FCGRT

Detects human FcRn. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Batoclimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Batoclimab (anti-FcRn) Biosimilar

Q: Is the Batoclimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Batoclimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Batoclimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Batoclimab that binds human FcRn.